KARD Company Profile and Key Details

Average 10-day trading volume of 289.63 thousand shares is below the 3-month average of 346.10 thousand, indicating normal recent market interest.

Kardigan, Inc. has 93.50 million shares outstanding. The public float is 51.76 million shares, elevated short interest at 2.09% of float. This equals 1.58 million shares. The short ratio is 4.47 days. Institutional investors hold 53.09% of the float. Insiders own 34.97%.

Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $51.00 to $37.00. The high target offers 145.9% upside. The low target suggests 78.4% downside. The mean target is $43.50. This offers 109.74% upside. Kardigan, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by 582.62%.

Kardigan, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.59. This means the shares are trading above this model’s fair value.

Kardigan, Inc. (NASDAQ:KARD) closed at $20.74 USD, losing -$1.18 (-5.38%) from the previous close of $21.92. The stock is currently mid-range between its 52-week high and low $16.25 and $27.00. With a market capitalization of about $1.85 billion, Kardigan, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 451.48 thousand shares, volume is running light vs its 52-week average. Headquartered in Princeton, NJ, Kardigan, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tassos Gianakakos, the company employs approximately 241 people and listed since June 18, 2026. Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist.

Our AI price prediction model suggests that Kardigan, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.34%, with price expected at $20.81 by September 17, 2026, within a range of $19.97 to $21.57 3-Month Outlook: Projected fall of -99.76%, reaching $0.05 by December 01, 2026, with a range of $0.00 to $0.23. 1-Year Outlook: Projected loss of -64.66%, with price at $7.33 by September 03, 2027, within a range of $7.17 to $7.61.

Valuation shows Kardigan, Inc. trading at a premium to the broader market with a P/E of -9.63. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $43.50, suggesting 109.74% upside. Our AI forecast model points to short-term strength (0.34% over two weeks), a medium-term fall (-99.76% over three months), and a longer-term loss (-64.66% over one year), with expected trading ranges indicating moderate volatility.

Kardigan, Inc. trades at a P/E ratio of -9.63, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.13 trading at moderately above to book value. The P/FCF stands at -16.6, also below market averages.